Why Bariatric Surgery Still Has the Stronger Long-Term Case Than GLP-1 Weight-Loss Drugs

GLP-1 weight-loss medications have changed the conversation around obesity treatment. That is a good thing. For many people, medicines such as semaglutide have helped reduce appetite, improve blood sugar, lower weight, and in some high-risk patients, reduce cardiovascular events. Tirzepatide, often discussed in the same public conversation although it is technically a dual GIP/GLP-1 medication, has produced even stronger weight-loss results in trials.

So this is not an “injections don’t work” article. They do work.

The real question is different: what happens over the long term?

Because long-term weight loss is not about what happens for a few months while motivation is high and treatment is new. It is about what still holds five years later. Ten years later. Twenty years later. It is about diabetes control, heart risk, medication burden, quality of life, and whether the treatment keeps working when real life becomes messy.

That is where bariatric surgery still has the stronger case for suitable patients.

GLP-1 drugs are powerful, but they are treatment-dependent

The best GLP-1 results are impressive. In the STEP 5 trial, semaglutide 2.4 mg produced an average weight loss of 15.2% at 104 weeks, compared with 2.6% on placebo [1]. In the SELECT trial, semaglutide produced sustained weight loss over four years and reduced major cardiovascular events by 20% in people with overweight or obesity and established cardiovascular disease, but without diabetes [2].

That deserves respect.

But the important detail is this: the benefit depends heavily on continued treatment.

In the STEP 1 extension study, participants who had lost 17.3% of their body weight on semaglutide regained 11.6 percentage points after stopping treatment. Put simply, they regained about two-thirds of the weight they had lost after the medicine was withdrawn: 11.6 divided by 17.3 equals roughly 67% [3].

Tirzepatide shows the same basic pattern. In the SURMOUNT-4 withdrawal trial, people who continued tirzepatide maintained and added to their weight loss, while those who stopped treatment regained a substantial amount of weight [4].

That does not mean GLP-1 medicines are bad. It means they behave like chronic medication. Like blood-pressure tablets, cholesterol medication, or diabetes medication, they work while they are being used. Stop the treatment, and the biology that drove the disease often returns.

For some patients, that is perfectly acceptable. But it changes the long-term conversation.

Real life is not a clinical trial

Clinical trials are controlled environments. Patients are selected, monitored, encouraged, followed up, and supplied with medication. Real life is different. People stop medication because of side effects, cost, supply problems, loss of motivation, pregnancy planning, travel, family pressure, work stress, or simply because weekly injections become too much.

A large real-world JAMA Network Open cohort study found that among adults using GLP-1 receptor agonists for overweight or obesity, 64.8% of patients without type 2 diabetes discontinued within one year. By two years, that figure was 84.4% [5].

That is a major long-term weakness.

A treatment cannot deliver long-term benefit if most people cannot stay on it. And this is where bariatric surgery has a different profile. Surgery is not easy, and it is not a shortcut, but once the operation is done, the main metabolic intervention has happened. The patient still needs follow-up, nutrition support, movement, protein, vitamins, and behaviour change. But they are not relying on a weekly prescription to keep the entire treatment active.

Bariatric surgery has the long-term data GLP-1 drugs do not yet have

This is the heart of the argument.

Modern GLP-1 medications are promising, but they do not yet have the same depth of 10-, 15-, and 20-year obesity outcome data that bariatric surgery has. Bariatric surgery has been studied for decades, across weight loss, diabetes, cardiovascular outcomes, cancer risk, survival, and quality of life.

The 2022 ASMBS/IFSO guidelines state that metabolic and bariatric surgery produces significant and durable weight loss, with durability demonstrated at 5, 10, and 20 years after surgery [6].

A 12-year study of Roux-en-Y gastric bypass published in the New England Journal of Medicine found that at 10 years, 72% of patients had maintained at least 20% weight loss from baseline [7]. That is a very different type of result from “weight loss while on medication.” It is durable weight loss years after a once-off anatomical and metabolic intervention.

The Swedish Obese Subjects study also found that bariatric surgery was associated with long-term weight loss and reduced overall mortality [8]. Another long-term analysis from the same study found fewer cardiovascular deaths and cardiovascular events in the surgery group compared with usual care [9].

A 2021 Lancet meta-analysis reported that metabolic-bariatric surgery was associated with substantially lower all-cause mortality and longer life expectancy compared with usual non-surgical obesity care [10].

That is why surgery still stands apart. The long-term evidence is not just about kilos lost. It is about disease trajectory.

Diabetes is where surgery becomes especially hard to beat

For patients with obesity and type 2 diabetes, bariatric surgery is not simply a weight-loss operation. It is metabolic treatment.

The STAMPEDE trial compared intensive medical therapy alone with intensive medical therapy plus bariatric surgery in patients with type 2 diabetes. At five years, surgery plus medical therapy was superior for glycaemic control, weight reduction, medication reduction, and quality-of-life measures [11].

That matters because diabetes is not a cosmetic disease. It affects the heart, kidneys, eyes, nerves, circulation, and long-term survival. If a treatment can reduce weight and reduce the need for diabetes medication while improving metabolic control, it deserves serious attention.

GLP-1 drugs also improve diabetes and cardiovascular risk. That is not in dispute. But again, the long-term issue is dependence. The medication must usually continue. Surgery, when successful and properly supported, can create a lasting metabolic shift that reduces the need for ongoing medication in many patients.

Surgery is not magic — and pretending it is would be dishonest

Bariatric surgery is not the right answer for everyone.

It is surgery. It carries risk. Patients need proper assessment, an experienced surgical team, anaesthetic evaluation, psychological readiness, nutrition support, and long-term follow-up. There can be complications. There can be reflux, strictures, ulcers, gallstones, nutritional deficiencies, weight regain, or the need for revision surgery. Lifelong supplementation and monitoring are part of responsible bariatric care.

Modern bariatric surgery is much safer than many people assume, but it should never be presented casually. Current evidence reports mortality around 0.1% to 0.13% and major complication rates under 5% in accredited centres [12]. Low risk is not the same as no risk.

The patient also has to participate. Surgery changes the biology, but it does not remove responsibility. Protein intake matters. Movement matters. Follow-up matters. Supplements matter. Eating patterns matter.

The difference is that surgery often makes the lifestyle change more achievable because it changes hunger, satiety, portion size, gut hormone responses, and metabolic signalling. It is not just “eat less.” It helps the body respond differently.

The fairest answer is not surgery versus medication — it is choosing the right tool

There are patients for whom GLP-1 medication may be the better first step. Someone with a lower BMI, someone not ready for surgery, someone with high surgical risk, someone needing to lose weight before an operation, or someone who has regained weight after surgery may benefit greatly from medication.

There are also patients for whom surgery may be the stronger long-term option: people with severe obesity, obesity-related diabetes, sleep apnoea, hypertension, fatty liver disease, mobility limitations, or repeated failed attempts at non-surgical weight loss.

The strongest future model may not be “surgery or medication.” It may be surgery and medication, used intelligently at different stages of the disease.

But if the question is blunt — which treatment currently has the stronger long-term evidence for suitable patients with severe obesity? — bariatric surgery still has the edge.

Not because GLP-1 drugs are weak.

Because bariatric surgery has something the drugs are still building: decades of durability data, long-term metabolic outcomes, survival evidence, and a treatment effect that does not disappear simply because a prescription is stopped.

GLP-1 medications have opened an important new chapter in obesity care. Bariatric surgery remains the chapter with the longest follow-up and the strongest long-term track record.

For the right patient, in the right hands, with the right follow-up, surgery is still the most proven long-term intervention we have.

Reference map for the numbered sources in the article

[1] The STEP 5 semaglutide trial reported mean body-weight change of −15.2% at 104 weeks with semaglutide versus −2.6% with placebo.
[2] The SELECT semaglutide analysis reported sustained weight loss up to 208 weeks and a 20% reduction in major adverse cardiovascular events in the SELECT cardiovascular outcomes trial population.
[3] The STEP 1 extension found that after semaglutide withdrawal, participants regained 11.6 percentage points of a prior 17.3% mean weight loss by week 120.
[4] The SURMOUNT-4 withdrawal trial found that stopping tirzepatide led to substantial weight regain, while continued treatment maintained and augmented weight loss.
[5] The JAMA Network Open real-world cohort study reported 64.8% one-year discontinuation among patients without type 2 diabetes and 84.4% discontinuation by two years.
[6] The 2022 ASMBS/IFSO guidelines state that bariatric surgery has durable outcomes over 5, 10, and 20 years and is superior to non-surgical methods for significant durable weight loss and obesity-related comorbidity improvement.
[7] The NEJM 12-year gastric bypass study reported that at 10 years, 72% of Roux-en-Y gastric bypass patients had maintained at least 20% weight loss from baseline.
[8] The Swedish Obese Subjects mortality study found bariatric surgery was associated with long-term weight loss and decreased overall mortality.
[9] The Swedish Obese Subjects cardiovascular analysis found bariatric surgery was associated with fewer cardiovascular deaths and lower incidence of cardiovascular events than usual care.
[10] The 2021 Lancet meta-analysis found metabolic-bariatric surgery was associated with lower all-cause mortality and longer life expectancy than usual obesity care.
[11] The STAMPEDE five-year trial found bariatric surgery plus intensive medical therapy was superior to intensive medical therapy alone for glycaemic control and weight reduction in patients with type 2 diabetes and BMI 27–43.
[12] Modern bariatric surgery safety data report mortality around 0.1% to 0.13% and major complication rates under 5% at accredited centres